Arch of foot – Talk Bio

Kathy High Takes Helm at GV, ARCH-Backed Eye Disease Biotech RhyGaze; Arvinas Sees Leadership Shift

3 months ago talkbio0Tagged Arch of foot, Arvinas, Changing, Granulovirus, GV, Kathy, Leadership, RhyGaze

Kathy High, RhyGaze, GV, ARCH, eye disease biotech, Arvinas, leadership changes

Tenvie Therapeutics Launches with $200 Million to Revolutionize Neurological Disease Treatment

4 months ago talkbio0Tagged Arch of foot, Denali, F-Prime Capital, Mubadala, Neurological diseases, Partner in relationship, small molecule therapies, Tenvie, venture

Tenvie Therapeutics, neurological diseases, small molecule therapies, Denali Therapeutics, ARCH Venture Partners, F-Prime Capital, Mubadala Capital

Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO

1 year ago talkbio0Tagged Arch of foot, Backed, Bayer, bleomycin/dacarbazine/lomustine/vincristine, Boundless, Checkpoint Kinase 1 Inhibitors, extrachromosomal DNA, IPO, Nasdaq Listing, Oncology Startup, Partner in relationship, Phase 1 Trials, Preliminary, Public Offering, Second Half of 2024, small molecule drugs, symbol

Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024